Clinical trials
Pulmonary Hypertension Due to Left Heart Disease clinical trials
Below are recruiting pulmonary hypertension due to left heart disease clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05714085RecruitingPhase 2/Phase 3
Vericiguat study for children with heart failure
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Los Angeles, CaliforniaAges 4 weeks–17 years - NCT05844462RecruitingPhase 3
Tadalafil for severe lung blood-pressure problems from COPD
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
Le Kremlin-Bicêtre, FranceAges 18–85 - NCT07214376Recruiting
Nerve ablation for pulmonary hypertension from left heart disease
This trial tests a device that uses a catheter to deliver energy to nerves around the pulmonary arteries, aiming to reduce high blood pressure in the lungs caused by left heart failure. It is for people with ongoing heart failure symptoms despite optimal medications.
Tucson, ArizonaAges 18–85 - NCT04484675RecruitingPhase 4
Milrinone during heart surgery for severe pulmonary hypertension
This trial tests whether giving milrinone through a vein and inhaled during mitral valve surgery helps people with severe pulmonary hypertension. The goal is to improve heart and lung blood-flow stability around the time of surgery.
Zagazig, Sharqia ProvinceAges 18 years+ - NCT07742046Enrolling by invitation
Heart blood flow scan for congenital heart disease
This study tests a new MRI technique to measure blood flow in the heart without invasive procedures. It may help doctors better understand and manage congenital heart conditions.
LausanneAges 16 years+ - NCT07473700RecruitingPhase 2
Study of TX000045 for lung scarring and high blood pressure in the lungs
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Phoenix, ArizonaAges 18–80 - NCT04808596Recruiting
Pulmonary hypertension registry and blood sample study
This study builds a registry and collection system for people with pulmonary hypertension, confirmed by a specific heart test. By joining, you help researchers learn more about the condition and may support future studies.
Kansas City, KansasAges 18 years+ - NCT05798923RecruitingPhase 2
LAM-001 for lung scarring with high blood pressure
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
Tucson, ArizonaAges 18–80 - NCT05937854RecruitingPhase 2
Tadalafil to help breathing in COPD with pulmonary hypertension
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
Aurora, ColoradoAges 35–89 - NCT06053580RecruitingPhase 2
Valsartan for pulmonary hypertension: protection study
This trial tests whether a blood pressure medicine called valsartan can help protect the lungs and heart in people with a specific type of pulmonary hypertension (Group 1 PAH). If you have PAH and are stable enough to walk 50 meters, you may be able to join.
Seattle, WashingtonAges 18–80 - NCT06336798RecruitingPhase 2
Pioglitazone for pulmonary hypertension from lung disease
This trial tests if pioglitazone, a medicine used for diabetes, can help people with high blood pressure in their lungs caused by chronic lung disease. The goal is to see if it improves how your cells use energy.
Atlanta, GeorgiaAges 18 years+ - NCT06526195Recruiting
A study of CardioMEMS and HeartMate 3 for advanced heart failure
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Phoenix, ArizonaAges 18 years+ - NCT06998329Recruiting
PAH diagnosis timing study
This study looks at the timing between first symptoms and diagnosis of pulmonary arterial hypertension (PAH). It aims to better understand how quickly patients get diagnosed after symptoms appear.
São Paulo, São PauloAges 18 years+ - NCT02061787Recruiting
Exercise testing to assess outcomes in pulmonary hypertension
This trial studies how well a treadmill/breathing exercise test can measure health outcomes in people with certain types of pulmonary hypertension. It may help your care team judge your status and track changes over time.
BeijingAges 5–100 - NCT07285655RecruitingPhase 3
Study of L606 for lung disease with high blood pressure in the lungs
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
Scottsdale, ArizonaAges 18–80 - NCT07537517Recruiting
Understanding heart failure and blood vessel pressure changes
This research study examines how certain biological pathways work in patients with heart failure who need heart catheterization (a procedure to measure heart pressures). By understanding these pathways, researchers hope to develop better treatments for pulmonary hypertension, a condition where blood pressure in the lungs becomes dangerously high.
Madrid, MadridAges 18 years+ - NCT07604805Recruiting
Chinese herbal medicine for severe lung blood pressure
This trial tests whether Qishen Yiqi Dropping Pills, a traditional Chinese herbal medicine, can safely improve symptoms and heart function in people with severe pulmonary hypertension (abnormally high blood pressure in the lungs). You would take this medicine alongside or instead of other treatments to see if it helps you walk farther and feel better.
Guangzhou, GuagdongAges 18–75 - NCT07662655RecruitingEarly Phase 1
PADN for pulmonary hypertension after mitral valve repair
This study tests a new procedure called pulmonary artery denervation (PADN) to lower high blood pressure in the lungs that persists after a mitral valve repair. It aims to see if this extra treatment improves symptoms and outcomes for people with this condition.
Xiamen, FujianAges 18–80 - NCT06846554RecruitingPhase 2
Study of APL-9796 for Pulmonary Hypertension with CardioMEMS Monitor
This trial tests a study drug called APL-9796 for people with pulmonary hypertension (PH). It may help by using your CardioMEMS monitor to see how well the drug works. You can take part only if you have a CardioMEMS implant and your PH is not too mild or too severe.
London, LondonAges 18–80 - NCT07082738RecruitingPhase 2
Study of AZD6793 for people with moderate to very severe COPD
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Birmingham, AlabamaAges 40 years+ - NCT05670132Recruiting
Heart and brain rehab for youth with congenital heart disease
This trial tests a combined heart and brain rehabilitation program for young people with moderate to complex congenital heart disease. The goal is to improve both heart health and thinking skills, such as memory and attention.
BrusselsAges 8–25 - NCT07366879Recruiting
Exercise program for newly diagnosed pulmonary hypertension
This study tests whether a home-based exercise program, added to your regular medications, can help people who are newly diagnosed with pulmonary arterial hypertension feel better and improve their daily function.
GlasgowAges 18 years+ - NCT01712620RecruitingPhase 2
Spironolactone for pulmonary arterial hypertension in stable patients
This trial studies whether spironolactone can improve pulmonary arterial hypertension, a disease that makes the blood vessels in the lungs work too hard. You may be eligible if your condition is confirmed by specific heart-lung pressure tests and your medication plan has been stable for at least 4 weeks.
Bethesda, MarylandAges 18–100 - NCT07318597RecruitingPhase 2
A study of an experimental drug for pulmonary arterial hypertension
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Aurora, ColoradoAges 18 years+
Hear when a new Pulmonary Hypertension Due to Left Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary hypertension due to left heart disease?
- Yes. Clin2 currently lists 40 recruiting pulmonary hypertension due to left heart disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary hypertension due to left heart disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary hypertension due to left heart disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
- Hypoplastic Left Heart Syndrome
- Pulmonary Artery Hypertension
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Idiopathic Pulmonary Arterial Hypertension
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.